Dolutegravir intermediate-1

• Description:

  Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV) -1 infection.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/Dolutegravir_intermediate-1.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(OC)C(C(C(O)=O)=CN1CC(OC)OC)=O)OC

• Molecular Formula:

  C13H17NO8

• Molecular Weight:

  315.28

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Sivaram Prasad, et al. Process for the preparation of dolutegravir . WO 2016125192 A2.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  Store at room temperature, keep dry and cool

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HIV-1

• CAS Number:

  [1335210-23-5]